# Forest Laboratories clinical trials: 168 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 168 trials with Forest Laboratories as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Forest Laboratories: 168 rows for $8.40, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/forest-laboratories

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 168
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 168, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 2, 2016 | NCT02788617 | Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage | Forest Laboratories | Observational | Completed | Infertility | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02788617) |
| April 8, 2016 | NCT02732327 | Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer | Forest Laboratories | Phase 2 | Terminated | Neoplasms, Febrile Neutropenia | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02732327) |
| February 1, 2016 | NCT02670551 | Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression | Forest Laboratories | Phase 3 | Completed | Bipolar Disorder, Depression | 488 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02670551) |
| February 1, 2016 | NCT02670538 | Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants... | Forest Laboratories | Phase 3 | Completed | Bipolar Disorder, Depression | 493 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02670538) |
| November 2, 2015 | NCT02593513 | Diafert for Embryo Selection and Fertility Improvement (DESTINy) | Forest Laboratories | Phase 3 | Completed | Infertility | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02593513) |
| November 2, 2015 | NCT02593461 | Diafert® for Embryo Selection and Fertility Improvement | Forest Laboratories | Phase 3 | Completed | Infertility | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02593461) |
| October 29, 2015 | NCT02590432 | An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With... | Forest Laboratories | Phase 4 | Completed | Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation | 828 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02590432) |
| October 26, 2015 | NCT02586272 | Diafert for Embryo Selection and Fertility Improvement | Forest Laboratories | Phase 3 | Completed | Infertility | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02586272) |
| September 24, 2015 | NCT02559817 | A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome... | Forest Laboratories | Phase 2 | Terminated | Irritable Bowel Syndrome With Constipation | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02559817) |
| September 24, 2015 | NCT02559570 | A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III... | Forest Laboratories | Phase 2 | Completed | Functional Constipation in Children Ages 6-17 Years | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02559570) |
| May 6, 2015 | NCT02436239 | A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder | Forest Laboratories | Phase 3 | Completed | Major Depressive Disorder | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02436239) |
| May 1, 2015 | NCT02431806 | Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder | Forest Laboratories | Phase 3 | Completed | Major Depressive Disorder | 552 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431806) |
| February 26, 2015 | NCT02372799 | Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) | Forest Laboratories | Phase 3 | Completed | Major Depressive Disorder | 473 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02372799) |
| November 11, 2014 | NCT02288325 | A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder | Forest Laboratories | Phase 4 | Completed | Depressive Disorder, Major | 644 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02288325) |
| October 22, 2014 | NCT02270983 | Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced... | Forest Laboratories | Phase 2 | Completed | Opioid-Induced Constipation | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02270983) |
| August 19, 2014 | NCT02220348 | A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically | Forest Laboratories | Phase 1 | Completed | Breast Feeding, Constipation, Irritable Bowel Syndrome | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02220348) |
| March 26, 2014 | NCT02097147 | Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo | Forest Laboratories | Phase 1 | Completed | Healthy | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02097147) |
| December 3, 2013 | NCT01999894 | Open-label Study of Safety and Tolerability of Memantine in Children With Autism | Forest Laboratories | Phase 2 | Completed | Autism, Pediatric Autism | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01999894) |
| August 9, 2013 | NCT01920074 | Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure | Forest Laboratories | Phase 4 | Withdrawn | Anal Fissure | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01920074) |
| June 14, 2013 | NCT01878292 | Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder | Forest Laboratories | Phase 3 | Completed | Major Depressive Disorder | 529 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01878292) |
| May 1, 2013 | NCT01844115 | Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder | Forest Laboratories | Phase 3 | Completed | Generalized Anxiety Disorder | 415 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01844115) |
| April 24, 2013 | NCT01838876 | Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive... | Forest Laboratories | Phase 3 | Completed | Major Depressive Disorder | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01838876) |
| January 11, 2013 | NCT01766401 | Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder | Forest Laboratories | Phase 3 | Completed | Generalized Anxiety Disorder | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01766401) |
| January 1, 2013 | NCT01758263 | Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment | Forest Laboratories | Observational | Unknown | Hypertension | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01758263) |
| October 29, 2012 | NCT01715805 | Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major... | Forest Laboratories | Phase 3 | Completed | Major Depressive Disorder | 1,022 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01715805) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 3 |
| Phase 2 | 33 |
| Phase 2/3 | 2 |
| Phase 3 | 88 |
| Phase 4 | 29 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 144 |
| Terminated | 20 |
| Withdrawn | 3 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Depressive Disorder, Major | 27 |
| Depression | 22 |
| Hypertension | 14 |
| Exocrine Pancreatic Insufficiency | 12 |
| Schizophrenia | 10 |
| Cystic Fibrosis | 9 |
| Fibromyalgia | 9 |
| Infections | 8 |
| Bipolar Disorder | 7 |
| Autistic Disorder | 5 |
| Alzheimer Disease | 5 |
| Pain | 5 |
| Constipation | 5 |
| Mania | 5 |
| Dyspepsia | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Nausea | 4 |
| Community-Acquired Pneumonia | 4 |
| Infertility | 4 |
| Fatigue | 4 |
| Coronary Artery Disease | 4 |
| Bacterial Infections | 3 |
| Abscess | 3 |
| Cellulitis | 3 |
| Atrial Fibrillation | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [Mortgage brokers in the United States](https://specstream.ai/data/businesses/mortgage-brokers/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
